Velmanase alfa - Chiesi Farmaceutici

Drug Profile

Velmanase alfa - Chiesi Farmaceutici

Alternative Names: ALPHA-MAN project; Lamazym; Lamzede; Recombinant lysosomal alpha-D-mannosidase; Recombinant lysosomal alpha-mannosidase; rhLAMAN

Latest Information Update: 09 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zymenex A/S
  • Developer Chiesi Farmaceutici; Zymenex A/S
  • Class Mannosidases; Recombinant proteins
  • Mechanism of Action Alpha-mannosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha-Mannosidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Alpha-Mannosidosis

Most Recent Events

  • 04 Apr 2018 Registered for Alpha-Mannosidosis (In adolescents, In children, In adults) in European Union, Norway, Iceland, Liechtenstein (IV) - First Global Approval
  • 26 Jan 2018 The Committee for Medicinal Products for Human Use recommends approval of Velmanase alfa for Alpha-Mannosidosis (In adolescents, In adults, In children) in European Union
  • 05 Oct 2016 Preregistration for Alpha-Mannosidosis (In adolescents, In children, In adults) in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top